Colchicine in Percutaneous Coronary Intervention

Exclusion Criteria

• •Colchicine use within 1 month
• •History of colchicine intolerance
• •Glomerular filtration rate \<30mL/minute or on dialysis (due to the need to adjust colchicine dose in this setting)
• •Active malignancy or infection (major confounder with increased inflammatory markers)
• •History of myelodysplasia (due to suggested cautionary use of colchicine in this setting)
• •High-dose statin load \<24 hours prior to procedure (major confounder that is known to reduce inflammatory levels in 12 to 24 hours)
• •Use of anti-inflammatory agents (except aspirin) within 5 halflives of the individual drug
• •Use of strong Cytochrome P450, Family 3, Subfamily A, Polypeptide 4 (CYP3A4) and/or P-glycoprotein inhibitors (e.g. ritonavir, ketoconazole, clarithromycin, cyclosporine, diltiazem and verapamil, again due to drug interactions)
• •Unable to consent
• •Participating in a competing study
• •Any significant condition or situation that may put the subject at higher risk, confound the study results or interfere with adherence to study procedures